Barbara E. Mahon, MD
Adjunct Professor
Boston University School of Public Health

MD, University of California San Francisco
MPH, University of California, Berkeley
AB, Harvard University
favorite icon LinkedIn

Dr. Mahon received her MD and clinical training in pediatrics from the University of California, San Francisco and her MPH from the University of California, Berkeley. She trained in CDC’s Epidemic Intelligence Service (EIS). Dr. Mahon is deputy chief of the Enteric Diseases Epidemiology and Surveillance Branch at the Centers for Disease Control and Prevention (CDC). The branch is responsible for national surveillance for enteric diseases. It conducts epidemiologic studies of the burden, trends, and food source attribution of foodborne diseases caused by Listeria , Salmonella, and E. coli O157, among other pathogens. The branch’s work also focuses on vulnerable populations, including older adults, young children, and other groups, with the goal of creating knowledge needed to protect people by preventing disease. Dr. Mahon has a broad background in infectious disease epidemiology, having worked on foodborne diseases, vaccine-preventable diseases, and sexually transmitted diseases in academic and industry positions as well as in government.

Adjunct Assistant Professor
Boston University Chobanian & Avedisian School of Medicine
General Pediatrics

Genetic and Environmental Factors in PCV7 Vaccine Effect
09/30/2004 - 09/29/2008 (PI)
HHS/Center for Disease Control
5 K01 CI00301 03

Rubella and Varicella Immunity Among Adolescents Seeking Care in an Urban Emergency Department
01/01/2003 - 12/31/2003 (PI)


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Silk BJ, Scobie HM, Duck WM, Palmer T, Ahmad FB, Binder AM, Cisewski JA, Kroop S, Soetebier K, Park M, Kite-Powell A, Cool A, Connelly E, Dietz S, Kirby AE, Hartnett K, Johnston J, Khan D, Stokley S, Paden CR, Sheppard M, Sutton P, Razzaghi H, Anderson RN, Thornburg N, Meyer S, Womack C, Weakland AP, McMorrow M, Broeker LR, Winn A, Hall AJ, Jackson B, Mahon BE, Ritchey MD. COVID-19 Surveillance After Expiration of the Public Health Emergency Declaration - United States, May 11, 2023. MMWR Morb Mortal Wkly Rep. 2023 May 12; 72(19):523-528. PMID: 37167154; PMCID: PMC10208372; DOI: 10.15585/mmwr.mm7219e1;
  2. Simon JK, Kennedy SB, Mahon BE, Dubey SA, Grant-Klein RJ, Liu K, Hartzel J, Coller BG, Welebob C, Hanson ME, Grais RF. Immunogenicity of rVSV?G-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials. Vaccine. 2022 Nov 02; 40(46):6599-6606. PMID: 36208978
  3. Massetti GM, Jackson BR, Brooks JT, Perrine CG, Reott E, Hall AJ, Lubar D, Williams IT, Ritchey MD, Patel P, Liburd LC, Mahon BE. Summary of Guidance for Minimizing the Impact of COVID-19 on Individual Persons, Communities, and Health Care Systems - United States, August 2022. MMWR Morb Mortal Wkly Rep. 2022 Aug 19; 71(33):1057-1064. PMID: 35980866; PMCID: PMC9400529; DOI: 10.15585/mmwr.mm7133e1;
  4. Gold JAW, Kelleher J, Magid J, Jackson BR, Pennini ME, Kushner D, Weston EJ, Rasulnia B, Kuwabara S, Bennett K, Mahon BE, Patel A, Auerbach J. Dispensing of Oral Antiviral Drugs for Treatment of COVID-19 by Zip Code-Level Social Vulnerability - United States, December 23, 2021-May 21, 2022. MMWR Morb Mortal Wkly Rep. 2022 Jun 24; 71(25):825-829. PMID: 35737571
  5. Barrett CE, Koyama AK, Alvarez P, Chow W, Lundeen EA, Perrine CG, Pavkov ME, Rolka DB, Wiltz JL, Bull-Otterson L, Gray S, Boehmer TK, Gundlapalli AV, Siegel DA, Kompaniyets L, Goodman AB, Mahon BE, Tauxe RV, Remley K, Saydah S. Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years - United States, March 1, 2020-June 28, 2021. MMWR Morb Mortal Wkly Rep. 2022 Jan 14; 71(2):59-65. PMID: 35025851; PMCID: PMC8757617; DOI: 10.15585/mmwr.mm7102e2;
  6. Cohn AC, Mahon BE, Walensky RP. One Year of COVID-19 Vaccines: A Shot of Hope, a Dose of Reality. JAMA. 2022 Jan 11; 327(2):119-120. PMID: 34932067
  7. Dolan SB, Mahon BE, Dowell SF, Zaidi A. Toward Understanding Death. Clin Infect Dis. 2021 12 15; 73(Suppl_5):S341-S342. PMID: 34910167; PMCID: PMC8672748; DOI: 10.1093/cid/ciab809;
  8. Mahon BE, Simon J, Widdowson MA, Samai M, Rogier E, Legardy-Williams J, Liu K, Schiffer J, Lange J, DeByle C, Pinner R, Schuchat A, Slutsker L, Goldstein S. Baseline Asymptomatic Malaria Infection and Immunogenicity of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein. J Infect Dis. 2021 12 01; 224(11):1907-1915. PMID: 34013349; PMCID: PMC8643414; DOI: 10.1093/infdis/jiab243;
  9. Morgan OW, Aguilera X, Ammon A, Amuasi J, Fall IS, Frieden T, Heymann D, Ihekweazu C, Jeong EK, Leung GM, Mahon B, Nkengasong J, Qamar FN, Schuchat A, Wieler LH, Dowell SF. Disease surveillance for the COVID-19 era: time for bold changes. Lancet. 2021 06 19; 397(10292):2317-2319. PMID: 34000258; PMCID: PMC8121493; DOI: 10.1016/S0140-6736(21)01096-5;
  10. Grais RF, Kennedy SB, Mahon BE, Dubey SA, Grant-Klein RJ, Liu K, Hartzel J, Coller BA, Welebob C, Hanson ME, Simon JK. Estimation of the correlates of protection of the rVSV?G-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials. Lancet Microbe. 2021 Feb; 2(2):e70-e78. PMID: 35544244
Showing 10 of 120 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 120 publications over 31 distinct years, with a maximum of 14 publications in 2012


Contact for Mentoring:

715 Albany St Talbot Building
Boston MA 02118
Google Map

Mahon's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department